NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its ...

James Manning / PA Images via Getty Images Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Allurion cited prior studies demonstrating that its gastric balloon, combined with its Virtual Care Suite, has helped patients lose weight while maintaining or even increasing muscle mass.

1 In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose ...

This patent covers additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology and the introduction of innovative features, particularly to the ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

If you can’t beat them then join them. In a bid to combat weakening financial performance, Allurion has revealed plans to initiate a clinical study evaluating its weight loss programme in ...

The U.S. Patent and Trademark Office granted Patent No. 12,209,677, which pertains to advancements in Allurion's proprietary Balloon technology, particularly improving the precision of the valve ...